Diabetes Home > Onglyza

Effects of Onglyza

There have been several studies that looked at the effects of Onglyza for type 2 diabetes.
Hemoglobin A1c
Hemoglobin A1c (HbA1c) is a test used to measure long-term blood sugar control. For people without diabetes, HbA1c results are usually less than 6 percent, while people with diabetes usually have higher results. In one study, people taking Onglyza lowered their HbA1c by 0.4 to 0.5 percent on average (depending on the dose), while people not taking it increased their HbA1c by 0.2 percent.
Studies have shown that the higher the HbA1c, the greater the chance for developing long-term problems related to diabetes. This includes problems such as heart disease, diabetic retinopathy, diabetic neuropathy, and diabetic nephropathy. By getting blood sugar levels under control with Onglyza, it may be possible to decrease the chances for developing these diabetes complications.
Blood Sugar Levels
In studies, Onglyza lowered fasting blood sugar by 9 to 15 mg/dL on average. The medication also lowered 2-hour postprandial blood sugar (blood sugar two hours after a meal) by 43 to 45 mg/dL on average.

When and How Do I Take It?

Some general considerations include the following:
  • Onglyza comes in tablet form. It is taken by mouth once a day.
  • This medicine can be taken with or without food.
  • You can take Onglyza at any time of day; however, you should try to take it at the same time every day.
  • For the medication to work properly, it must be taken as prescribed.

Onglyza Dosing Information

The dosage that your healthcare provider recommends will vary depending on a number of factors, including:
  • How well your diabetes is controlled
  • Other medical conditions you may have (especially kidney disease)
  • Other medications you may currently be taking.
As is always the case, do not adjust your dose unless your healthcare provider specifically instructs you to do so.
(Click Onglyza Dosage for more information.)
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):
Other Articles in This eMedTV Presentation




Related Channels

eMedTV Links
Copyright © 2006-2021 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.